Skip to main content

Table 2 Laboratory investigations, abdominal ultrasound, and liver stiffness measurements in both HCV patients post chemotherapy (cases) and HCV patients without cancer (controls)

From: Efficacy and safety of direct-acting antivirals for HCV in patients with extrahepatic malignancies: real-life experience

 

HCV patients post chemotherapy

Mean ± SD

HCV patients without cancer

Mean ± SD

p-value

ALT (IU/L)

58.6 ± 37.36

58.7 ± 102.6

0.993

AST (IU/L)

59.6 ± 31.8

54.2 ± 55.6

0.440

Baseline HCV RNA × log 10

5.63 ± 0.91

5.54 ± 0.95

0.63

AFP (U/L)

10.8 ± 16.86

9.7 ± 15.13

0.712

Albumin (g/dl)

4.02 ± 0.65

3.99 ± 0.90

0.76

Total bilirubin (mg/dl)

0.80 ± 0.40

1.06 ± 1.17

0.048

Indirect bilirubin (mg/dl)

0.51 ± 0.42

0.50 ± 0.28

0.98

TSH

2.23 ± 1.8

1.74 ± 1.08

0.15

WBC × 103 mm3

6.04 ± 3.98

7.13 ± 10.46

0.37

ANC × 103 mm3

4.07 ± 8.21

6.51 ± 12.23

0.23

Hb (g/l)

13.22 ± 1.85

12.94 ± 1.50

0.27

Platelets × 103 mm3

173.8 ± 71.8

184.83 ± 82.4

0.35

PC%

84.81 ± 16.36

86.37 ± 10.52

0.537

INR

1.12 ± 0.16

1.10 ± 0.13

0.38

Creatinine (mg/dl)

0.86 ± 0.26

0.91 ± 0.79

0.54

Glucose (mg/dl)

107.15 ± 31.66

109.52 ± 30.73

0.66

HbA1C%

6.34 ± 1.09

7.32 ± 1.46

0.013

Liver ultrasound known cirrhotic

N (%)

17 (20.5%)

N (%)

12 (13.6%)

Total

29 (17%)

0.233

Liver stiffness (Kpa)

15.28 ± 8.12

23.78 ± 16.77

0.28

FIB-4 calculation

3.14 ± 2.47

2.95 ± 3.06

0.655

  1. p ≤ 0.05 is significant